论文部分内容阅读
How to design a fluorescent probe for GPCR? A case in α1-adrenergic receptors
【机 构】
：
Department of Medicinal Chemistry,School of Pharmacy,Shandong University,Shandong 250012,China
【出 处】
：
2015年全国药物化学学术会议暨第五届中英药物化学学术会议
【发表日期】
：
2015年3期
其他文献
英国阿斯利康公司报道了一种新型成纤维细胞生长因子受体(FGFR)高选择性抑制剂——AZD4547[1].AZD4547 主要利用胃癌肿瘤细胞表面高表达的FGFR受体作为靶点,可作为ATP 与FGFR 结合的竞争性抑制剂,抑制肿瘤细胞增殖,使肿瘤细胞凋亡.目前,AZD4547 正处于胃癌治疗的临床Ⅱ期研究中.
Identification and Structure-Activity Relationships of Novel Dual-acting Agents to Improving Therape
The development of estrogen receptor(ER)ligands has emerged as active study field in fight against breast cancer,some of these have been termed selective estrogen receptor modulators(SERMs)because the
Multidrug resistance(MDR)is a major obstacle that leads to most tumor treatment failures.Thus,it is imperative to develop new approach and design new chemotherapy to overcome this challenge.Recently,t
糖尿病是当前威胁全球人类健康的最重要的慢性非传染性疾病之一.根据国际糖尿病联盟(IDF)的最新统计,2014年全球糖尿病患者人数已达3.87亿,且到2035年估计将有5.92亿病例,而目前中国成人糖尿病患者数量预计已超过1亿,居全球首位.因此,治疗糖尿病的新型药物的研发是全球关注的热点之一.
Microbial infections endanger public health unremittingly and cause a huge economic burden to our society.Numerous efforts have been made to develop molecules which are able to inhibit pathogens.Novel